Scientific Publications

Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL),

American Society of Hematology Annual Meeting, Ghobadi et al, December 2023

Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia

Science Translational Medicine, Berrien-Elliot et al, February 2022

Memory-like differentiation enhances NK cell responses to melanoma

Clin Cancer Res, Marin et al, June 2021

Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia

Cancer Discovery, Berrien-Elliott et al, December 2020

CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas

Blood, Gang et al, November 2020 

Memory-like natural killer cells for cancer immunotherapy

Seminars in Hematology, Gang et al, November 2020 

Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies

Best Practice & Research Clinical Haematology, Cooper and DiPersio, December 2019

An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies

Leukemia, Cooper et al, February 2018

Cytokine-Induced Memory-Like Differentiation Enhances Unlicensed Natural Killer Cell Antileukemia and FcγRIIIa-Triggered Responses

Biol Blood Marrow Transplant, Wagner et al, March 2017 

Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.

Science Translational Medicine, Romee et al, September 2016

Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells.

Biol Blood Marrow Transplant, Leong et al, April 2014

Cytokine activation induces human memory-like NK cells.

Blood, Romee et al, December 2012

Latest News

Wugen to Present Clinical Data at the 2024 ASH Annual Meeting Ahead of Pivotal Trial Launch of Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy WU-CART-007

— Data Support Start of First Pivotal Trial for an Off-the-Shelf, Allogeneic CD7-Targeted CAR-T Cell …

Wugen to Initiate a Pivotal Trial for Its Investigational, Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy, WU-CART-007, in Patients with Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia or T Cell Lymphoblastic Lymphoma

— First Pivotal Trial for an Off-the-Shelf, Allogeneic CD7-Targeted CAR-T Cell Therapy to Begin in …

Cherry T. Thomas, M.D., Joins Wugen as Chief Medical Officer, Bringing Cell Therapy Expertise Across Clinical Development, Regulatory, and Medical Affairs as the Company Embarks on a Pivotal Trial for its Investigational, Allogeneic CD7-Targeted CAR-T Cell Therapy

ST. LOUIS, MO and SAN DIEGO, CA, Nov. 12, 2024 – Wugen, Inc., a clinical-stage U.S. …

ST. LOUIS

4260 Forest Park Ave
Suite 100
St. Louis, MO 63108
(636) 385-5306

SAN DIEGO

9880 Campus Point Dr
Suite 430
San Diego, CA 92121

SOCIAL

Copyright © 2024 Wugen. All Rights Reserved.

Privacy Notice
a COGNEO design